cme ARTICLE lular origins of HO remain elusive. Some bona fide contributing cell populations have been found through genetic lineage tracing and other experiments in vivo, and various other candidate populations have been proposed. Nevertheless, because of the difficulties in establishing cellular phenotypes in vivo and other confounding factors, the true identities of these populations are still uncertain. This review critically evaluates the accumulating data in the field. The major focus is on the candidate populations that may give rise to osteochondrogenic lineage cells directly, not the populations that may contribute to HO indirectly. This issue is important not solely because of the clinical implications, but also because it highlights the basic biological processes that govern bone formation. [Orthopedics. 2014; 37(5): 329-340.] H eterotopic ossification (HO), which commonly refers to bone formation at an abnormal anatomical site, is a serious health problem. Typical acquired HO is a common and costly complication of various types of traumatic events, including fracture, total joint replacement (TJR), traumatic brain injury (TBI), spinal cord injury (SCI), or combat-related trauma.
1,2 Cardiovascular calcification, an atypical acquired HO, is commonly associated with calcific aortic stenosis and other highly prevalent cardiovascular conditions that can eventually lead to early cardiovascular mortality. 3, 4 By contrast, hereditary syndromes of HO, such as fibrodysplasia ossificans progressiva (FOP) and progressive osseous heteroplasia (POH), are rare but progressive and potentially life-threatening disorders. 5, 6 Gain-of-function mutations of activin A receptor, type I (ACVRI), a type I bone morphogenetic protein (BMP) receptor, are known to cause FOP, and loss-of-function mutations of the imprinting guanine nucleotide binding protein, alpha stimulating (GNAS) complex locus cause POH. Nevertheless, the identity of the precursor cells that actually differentiate along the osteochondrogenic lineage to form HO-the so-called bona fide in vivo HO contributors-remains unclear in these disorders as well as in acquired HO. Thus, a broad spectrum of various cell populations have been proposed as candidates to be HO contributors (Table) .
The aims of the current review are to: 1. Evaluate candidate cell populations as HO contributors and delineate the hierarchical relationships among these populations, based on current data; 2.
Objectively weigh the experimental designs and techniques underlying the identification of putative HO contributors and discuss potential limitations;
3.
Clarify the profound confusion about the phenotypes of candidate populations in the literature; 4.
Critically evaluate the mechanisms underlying osteogenic induction of different contributing populations;
5.
Contrast the fundamental cellular differences between HO and normal skeletogenesis to identify potential disease-specific targets; and 6. Briefly discuss the practical implications and future directions.
cAndidAte PoPulAtions
The numerous candidate populations can be categorized according to their original germ layer (ectoderm, mesoderm, or endoderm), their original location (local or bone marrow/circulating), or their stemness (pluripotent and multipotential stem cells, bipotential progenitors, committed progenitors, or terminally differentiated cells).
Candidate Populations of Ectoderm Origin
There are only limited data that suggest that ectoderm-derived cells contribute to HO. [7] [8] [9] As early as the 1970s, Anderson 9 reported that FL, HeLa, and other nonmurine epithelial cells are capable of inducing chondro-osseous differentiation when brought into contact or close proximity with mouse thigh mesenchymal cells. Anderson 9 hypothesized that short-range diffusion of inductive substance(s) and/ or direct inductive stimuli from epithelial cells might be responsible for the osteogenic activities. Boyan et al 7 later reported that intramuscularly implanted epithelial cell lines (FL and WISH cells) produced tumors and induced large islands of bone with focal areas of cartilage immediately adjacent to the tumors. Although the consistent finding was interesting, these studies did not address the key question of which cells-donor, host, or both-gave rise to osteogenic lineage cells and turned into bone.
Rutherford et al 8 further reported that BMP-7-transduced human oral keratinocyte cells (HOKC) induced ectopic bone. To further clarify whether these cells give rise to osteogenic lineage cells themselves, they implanted BMP-7-transduced HOKC into a diffusion chamber that excluded the host cells from infiltrating into and donor epithelial cells out of the chamber. They found that no bone-like tissue formed within diffusion chambers, although ectopic bones still formed close to the implanted diffusion chamber. 8 These observations suggested that the host cells, not donor epithelial cells, turned into bone in response to osteogenic factors.
Theoretically, cells of ectoderm origin could give rise to osteogenic lineage cells and directly contribute to HO through the process of epithelial-to-mesenchymal transition (EMT). Epithelial-tomesenchymal transition was a paradigm that evolved first from observations of early embryonic development, and EMT is a necessary first step for normal embryonic skeletogenesis. In adults, EMT also plays a key role in various conditions such as fibrosis, wound repair, inflammation, and malignancy. 10 Epithelialto-mesenchymal transition can generate cells with stem cell properties in vitro, 11 and theoretically such epithelium-derived mesenchymal cells could then give rise to osteogenic lineage cells and contribute to HO. However, there are currently no data to substantiate this hypothesis. Moreover, studies of POH, which is characterized by HO formation in skin (an ectoderm derivative), find no evidence of ectodermal cell contribution to HO. 12 To summarize, currently available data suggest that epithelial cells may secrete BMP or other osteogenic factors and thereby contribute to HO indirectly, but they do not directly give rise to osteolineage cells.
Candidate Populations of Endoderm Origin
Although some observations suggest that cells of endoderm origin can contribute directly to HO, the overwhelming body of evidence indicates that endodermal cells contribute to HO only indirectly, similar to cells of ectodermal origin. The available data supporting a possible role for endodermal lineage cells come from 3 lines of evidence.
Data From In Vitro Experiments. Aguilar-Vázquez et al 13 reported that human umbilical vein endothelial cells (ECs) can differentiate along an osteogenic lin- 17 identification of such cells is problematical; (2) the number of putative CEPCs in peripheral blood is exceedingly low, which makes it implausible that they have a significant effect on pathophysiological processes, such as HO; and (3) there is no evidence that CEPCs actually contribute to HO in vivo.
Data In Vivo. Similar to cells of ectodermal origin, ECs can undergo a process termed endothelial-mesenchymal transition (EndMT), which is of importance in mediating many physiological and pathological processes. The observation that prostate tumor ECs can undergo EndMT and generate ectopic calcification is consistent with the idea that cells of endoderm origin could be contributors to HO. 18 Furthermore, constitutively activated ACVRI (found in FOP) caused morphological changes of ECs to mesenchymal-like cells and induced coexpression of the mesenchymal markers in vitro, a process similar to EndMT. 19 Importantly, these cells could differentiate into the osteogenic lineage. 19 Cells in FOP chondrogenic lesions coexpress Tie2 and vWF, putative endothelial markers, with the chondrogenic gene SOX9, whereas osteogenic lesions coexpress Tie2 and vWF with the osteogenic marker OCN. 19 These observations were interpreted as evidence that EC can be contributors to HO. Furthermore, Cre-lox-based genetic lineage tracing in vivo with Tie2-cre also found that Tie2-labeled cells contribute significantly to all stages of HO. 20, 21 The current authors also found that Tie2-labeled cells contribute significantly to normal skeletogenesis (Figure) . Unfortunately, Tie2 is not a specific marker of ECs, which limits any conclusions about lineage contributions to HO based on Tie2 expression. Tie2 is expressed by at least 3 distinct cell types: ECs, proangiogenic monocyte cells of hematopoietic origin, and pericyte precursors of mesenchymal origin. In addition, in the lineage-tracing studies cited previously, Tie2 expression was also detected in BMP-induced lesional cells themselves, raising the possibility that Cre-dependent labeling resulted from de novo Tie2-Cre expression rather than reflecting a direct relationship with the Tie2 + lineage. 21 Importantly, transplantation of the endothelial fraction of Tie2 + cells (Tie2   +   CD31 + ) does not contribute to HO, whereas the nonendothelial fraction of Tie2 + cells (Tie2 + CD31 -) does contribute. Moreover, lineage tracing with another Cre line, VECadherin-Cre, which specifically labels endothelium/endothelial precursors, did not contribute to HO in an appreciable manner. 21 Together, these data strongly suggest that Tie2 + progenitor cells that contribute to HO in vivo are not of endothelial origin. 21 Thus, there are no convincing data that endodermal cells themselves give rise to osteogenic lineage cells in vivo. In contrast, substantial evidence suggests that ECs regulate osteogenic differentiation of other cells (mesenchymal cells) and contribute to HO indirectly, likely through mechanisms of paracrine or ECmesenchymal cells crosstalk. This leaves cells of mesoderm origin as the major direct contributors to HO.
Candidate Populations of Mesoderm Origin
Because many proposed candidate populations are of mesoderm origin, the authors review these populations sequentially according to their stemness.
Mesenchymal pancreas, 64 lung, 65 or amniotic fluid 66 by simple plastic-adherent culture. Mesenchymal stem cell-like cells can also come from circulation or suspension culture. [67] [68] [69] Pufe et al 70 also reported that peripheral venous blood contained programmable cells of monocytic origin (PCMOs) that have multilineage potential comparable with that of MSCs and can generate collagen type II-producing chondrocytes.
The characteristic features of MSCs are the abilities to self-renew and to differentiate into all mesoderm-type lineages, including osteoblasts, chondrocytes, adipocytes, smooth muscle cells, and myocytes, but not hematopoietic cells. Mesenchymal stem cells have been used to produce bony implants and in the repair of bony defects, 48 and the potential of human MSCs for osteogenic differentiation has been confirmed in immunocompromised mice. 71 Choi et al 72 also reported that undifferentiated human adipose tissue-derived MSCs can differentiate into osteocytes or osteoblasts in athymic nude rat calvaria. These observations suggest MSCs as a prime candidate population for contributing to HO. Although unequivocal demonstration of MSC contribution to HO has not been possible because of technical limitations and the lack of unequivocal MSC-specific markers, independent data from lineage tracing and other experiments provide strong evidence that tissue-resident MSC/progenitor cell populations represent bona fide cells of origin for HO. 2, 21 Wosczyna et al 21 reassessed Tie2 + progenitors and found that, unlike the endothelial fraction of Tie2, the nonendothelial fraction consistently incorpo- 21 A recent lineage-tracing study by Kan et al 2 suggested that another subpopulation of mesenchymal progenitor/stem cells, glutamate aspartate transporter (GLAST)-expressing cells, may also be a contributor to HO. They tested 2 Cre lines, GLAST-CreERT and FoxD1-Cre, and found that both of these Cre lines labeled similar mesenchymal populations in subcutaneous connective tissue and in the interstitium of skeletal muscles with slightly different labeling profiles. Interestingly, many of the labeled cells, either GLAST-CreERT or FoxD1-Cre labeled, were closely associated with the vasculature but did not colocalize with EC markers. Remarkably, the FoxD1-Cre-labeled cells contributed significantly to normal endogenous bone formation, but the contribution of the FoxD1-Cre-labeled population to HO was negligible. By contrast, GLAST-CreERT-labeled cells did not contribute significantly to normal bone formation, but they contributed significantly to HO at all stages. 2 Colabeling studies indicate that the FoxD1-Cre-and GLAST-CreERTlabeled cells partially overlap with each other (both colabeled with a battery of mesenchymal progenitor/stem cell markers), but both only minimally colabel with Tie2, suggesting that they are largely independent populations. 2 Significant numbers of FoxD1 + and Tie2 + , but not GLAST-CreERT + cells are found within bone marrow (Figure) , suggesting that GLAST-CreERT-labeled cells that contribute to HO do not arise from bone marrow. FoxD1
+ mesenchymal cells give rise to pericytes, and FoxD1-derivative interstitial cells expand and differentiate into SMA+ myofibroblasts during fibrosis in the kidney, 73 consistent with the possibility that they are stem cells. However, the multipotentiality of GLAST-CreERT-or FoxD1-labeled cells has not been directly tested, and it is unclear whether GLASTCreERT-and/or FoxD1-labeled cells are indeed MSC or just bipotent or even unipotent progenitors. Moreover, the precise hierarchical relationship between FoxD1 + , Tie2 + , and GLAST-CreERT + populations is still unclear.
Mesenchymal Progenitor Cells. Mesenchymal progenitor cell is a general term that refers to any undifferentiated cell of mesenchymal origin, excluding progenitor cells of hematopoietic origin. This term is also sometimes used interchangeably with MSC and others, such as fibroblasts/fibrocytes, which creates confusion in the field. Another confusing fact is that mesenchymal progenitor cells can be tripotent, bipotent, or unipotent progenitor cells. Numerous reports suggest that both local and circulating mesenchymal progenitor cell populations may contribute to HO. As early as 1975, Buring 74 proposed that the cell populations that develop into osteoblasts and osteocytes in response to osteoinductors are the progeny of perivascular mesenchymal cells. Later experiments showed that human skeletal muscle contains osteogenic progenitor cells. 75, 76 These cells can be easily cultured and expanded based on cell adhesion characteristics, but the true identities of these highly proliferative cells (positive for HOP-26, a marker of pericytes), are unclear.
In a grafted periosteum model, Ueno et al 75 found that grafted periosteum forms bone by endochondral ossification and that the osteogenic progenitor cells in the fibrous layer of long bone contribute to chondrogenesis. Analyses in vitro and lineage-tracing experiments in vivo in a new bone formation (fracture-healing) model with a smooth muscle actin-CreERT2 (SMA-CreERT2) confirmed the osteogenic phenotype of smooth muscle a-actin (aSMA)-positive mesenchymal progenitor cells. 76 55 as well as adipogenic, chondrogenic, and myofibrogenic potential, similar to MSCs. However, it has been reported that although osteogenic VICs displayed an osteoblast-like phenotype, there were stark differences between the VIC-derived cells and other true osteoblastic cell types, implying that VICs may not have true osteogenic potential. 77 In keeping with the uncertainty about the contribution of the general mesenchymal progenitor cell pool to HO, some subpopulations, such as muscle satellite cells, have been virtually excluded as potential contributors to HO, whereas the evidence for others, such as circulating osteogenic mesenchymal precursors, is stronger. 82 examined the contribution to HO of bone marrow-derived osteoblast progenitor cells (MOPCs) in a BMP-induced model following GFP + bone marrow transplantation in mice and found a significant number of GFP + osteoblastic cells in the newly generated HO. This study suggests that bone marrow-derived MOPCs could be an important contributor to HO in vivo. In a subsequent study, Otsuru at al 83 further analyzed cell surface markers of these MOPCs and found that they express CD44 and CXCR4 but not hematopoietic (eg, CD45) or endothelial lineage markers, suggesting a mesodermal origin of these cells. Notably, MOPCs are not the same as either the previously mentioned CEPC 15 or the circulating osteogenic precursor cells reported by Suda et al. 84 Circulating osteogenic precursor cells are bone marrow-derived collagen I + /CD45 + mononuclear adherent cells, which are present in early preosseous fibroproliferative lesions in patients with FOP and HO in a murine in vivo implantation assay. 84 Because these cells are CD45 + , they are likely hematopoietic in origin. Zvaifler et al 85 reported that in the circulation of normal individuals, there is a small population of CD34 -mesenchymal precursor cells that proliferate rapidly in culture as an adherent population but with variable morphologies. These cells can differentiate into several lineages, including fibroblasts, osteoblasts, and adipocytes. 85 Choi et al 86 91 reported that osteoprogenitor cells responsible for HO originate predominantly from bone marrow but also from local (hip abductors) sources. However, after bone marrow transplantation into an FOP patient, cells of hematopoietic origin contributed only to the early inflammatory and late marrowrepopulating stages of BMP-4-induced HO but were not represented in the fibroproliferative, chondrogenic, or osteogenic stages. 92 Furthermore, lineage tracing in vivo with multiple hematopoietic lineage markers, such as Lyz-Cre (which labels the hematopoietic stem cell/monocyte/ macrophage lineage), CD19-Cre (B-cells lineage), and LCK-Cre (T-cells lineage), found no evidence that circulating hematopoietic progenitors contribute directly to HO. 1 Overall, although the data for the hematopoietic precursor cells convincingly exclude these cells as direct contributors to HO, the current data for nonhematopoietic circulating mesenchymal precursor cells are insufficient to draw a firm conclusion.
Other 94 also reported that oxidative stress-mediated decorin glycosaminoglycan (GAG) chain synthesis triggers transforming growth factor-ß signaling and osteogenic differentiation of vascular SMCs in vitro. Shimizu et al 95 further reported that azelnidipine, a dihydropyridine subclass of calcium channel blockers, inhibits Msx2-dependent osteogenic differentiation and matrix mineralization of vascular SMCs in vitro. Using an SMC-specific SM22-Cre line, Speer et al 4 found that SM22-Cre-labeled cells gave rise to osteochondrogenic precursor and chondrocyte-like cells in calcified blood vessels of matrix Gla protein deficient (MGP-/-) mice in vivo. Furthermore, they found that the potential fate change of SMCs occurred before calcium deposition. Based on these data, they hypothesized that adult SMCs can transdifferentiate and that SMC transdifferentiation is an important process that drives vascular calcification. 4 Similarly, Bobryshev 96 also found some SMCs with a reduced content of aSMA (an SMC marker) and increased cme ARTICLE Sox9 (a chondrocyte or chondroprogenitor marker) in atherosclerotic plaques in vivo, again suggesting that transdifferentiation of SMC into chondrocytes contributes to atherosclerotic calcification.
The term transdifferentiation was originally coined by Selman and Kafatos 97 in 1974 to describe the change in cell properties as cuticle-producing cells became salt-secreting cells in silk moths undergoing metamorphosis. Currently, transdifferentiation is defined as a process where one mature somatic cell type transforms into another mature somatic cell without undergoing an intermediate pluripotent state or progenitor cell type. 98 Although transdifferentiation has been demonstrated frequently in vitro, only rare examples of transdifferentiation have been shown in vivo. Thus, the physiological or pathophysiological significance of this process in vivo is still in question. Furthermore, transdifferentiation is not the only possible interpretation of the aforementioned data. For example, based on other lineagetracing experiments, it is reasonable to argue that the SM22-Cre-or aSMA-labeled cells that contributed to HO may actually be mesenchymal progenitor cells or even myofibroblasts, not SMCs. Grcevic et al 76 posited that the aSMACre-ERT2-labeled cells that contribute to ossification are mesenchymal progenitor cells, not SMCs. In addition, Lounev et al 20 found that another SMC-specific Cre line, SMMHC-Cre, did not contribute cells to BMP-induced HO, which argues against a direct contribution of SMCs to HO. Furthermore, because myofibroblasts are also aSMA + (and colabel with SM22), it is possible that SM22-Cre-labeled cells are actually myofibroblasts, not to mention the additional possibility of cell fusion. Thus, the issue of whether SMCs have osteogenic potential is unresolved and awaits the development of a Cre line that exclusively labels SMCs.
Fibroblasts and fibrocytes are thought to be 2 states of the same cells, and currently there is a tendency to call both forms fibroblasts. Although all fibroblasts are morphologically similar, they are likely heterogeneous. For example, clonal analysis of dermal fibroblasts showed that 6.4% of the single-cell-derived clones were tripotent, 19.1% of the clones were bipotent, and 10.6% of the clones were unipotent, suggesting that fibroblasts comprise a heterogeneous population including progenitors with various levels of differentiation potential. 99 For example, it was reported that it is possible to isolate a multipotent MSC subpopulation from human gingival fibroblasts by culturing on chitosan membranes. 100 Adding to the confusion, fibroblasts are sometimes referred to as myofibroblasts, especially in their activated differentiated state, 101 and the term fibrocytes has sometimes been used interchangeably with mesenchymal progenitor cells. 102, 103 Because there are apparently multipotential subpopulations in fibroblasts, it is not surprising that fibroblasts can reportedly differentiate into both osteoblastic 104 and osteoclast-like cells. 105 Numerous reports have suggested the existence of circulating fibrocytes, and Choi et al 86 found that human circulating fibrocytes have the capacity to differentiate osteoblasts and chondrocytes. However, the contribution of fibroblasts/ fibrocytes to HO in vivo has not been vigorously tested, partially due to a lack of specific markers and Cre lines.
Myofibroblasts are intriguing cells that include phenotypic traits of both fibroblasts and SMCs. They are a-SMA + fibroblast-like cells that are closely associated with connective tissue matrix remodeling/ repair 106 and other pathological conditions. Myofibroblasts are found subepithelially in many mucosal surfaces and are involved in fibrosis, wound strengthening, and contraction. Confusingly, pericytes, another mesenchymal cell subpopulation, are sometimes called modified myofibroblast cells.
Myofibroblasts may be derived from many different origins, including SMCs, stellate cells, mesenchymal progenitor cells resident in a stromal tissue, circulating mesenchymal precursors, or even epithelial cells through EMT. 107 In turn, myofibroblasts are capable of differentiating into various cell types both in vitro and in vivo, including calcified vascular cells and osteoblasts, and are known to be involved in the ossification of heart valves and arteries. 108 Because myofibroblasts colabel with SM22, some of the previously discussed findings about the putative osteogenic potential of SMCs may actually reflect the lack of distinction from myofibroblasts. 109 Pericytes, also known as Rouget cells or mural cells, are defined by their anatomic features in vivo. They are contractile cells that wrap around the ECs of capillaries and venules, where they play key physiological roles through communication with ECs. Recently, it has become appreciated that these cells have impressive stem/progenitor cell-like features. Pericytes reportedly have osteogenic potential in vitro 110, 111 and in vivo 112 and are capable of giving rise to cells of multiple lineages, including chondrocytes, adipocytes, and fibroblasts, as well as osteoblasts. Some investigators even believe that all MSCs are pericytes, 113 and it is conceivable that pericytes and MSCs are 2 states of the same cells, similar to fibroblasts and fibrocytes. Interestingly, a subpopulation of pericytes are among the cell types that express GLAST. 114 More importantly, the characteristic anatomic distribution and the labeling pattern of GLAST-CreERT-labeled cells in the recent study by Kan et al 2 are consistent with the idea that some or all of the these GLAST-CreERT-labeled cells that contribute to HO may be pericytes. However, a lineage-tracing study with an NG2-Cre line (intended to label pericytes) showed no significant contribution of labeled cells to HO. 115 Nevertheless, the heterogeneity of pericytes 114 and the lack of validation of the NG2-Cre line make it unclear whether these negative data are sufficient to exclude the candidacy of pericytes.
contrAst between HeterotoPic ossificAtion And normAl skeletogenesis
Although there is substantial debate about the cellular origins of HO, it has generally been thought that the processes leading to HO and the formation of normal bone are largely the same because HO produces bone that faithfully replicates the appearance of normal bone. However, studies of the cellular origins of HO provide substantial evidence to challenge this dogma:
(1) It is known that EMT is a necessary first step for normal, embryonic skeletogenesis. Although EMT can also generate cells with properties of stem cells in vitro, 11 there is currently no evidence that epithelia can give rise to osteogenic lineage cells and/or contribute to HO through EMT in vivo in adults. This is indirect evidence that embryonic skeletogenesis and HO in adults may have different cellular origins.
(2) In a recent study, Kan et al 2 found that FoxD1-Cre-labeled cells contribute significantly to normal skeletogenesis but not to HO at any stage, whereas GLASTCreERT-labeled cells are just the opposite (ie, they do not contribute to normal skeletogenesis but are a major contributor to HO). This provides direct evidence of different cellular origins for embryonic skeletogenesis and HO in adults.
(3) Nevertheless, Tie2-labeled cells contribute to both HO and normal skeletogenesis (Figure) , suggesting that HO and normal skeletogenesis are not completely unrelated and that some populations may participate in both processes.
Understanding the differences in the cellular mechanisms underlying HO and normal skeletogenesis is not only of high scientific interest but will also be critical for identifying disease-specific molecular loci for therapeutic intervention.
conclusion
The preponderance of evidence suggests that mesenchymal-not endodermal or ectodermal-populations are the major bona fide populations of cells that contribute to HO. However, more detailed studies in vivo are necessary to completely exclude the candidacies of endodermal or ectodermal populations.
It is likely that more than one subpopulation of stem/progenitor cells contributes to HO, and further studies are necessary to identify the predominant contributing subpopulations. This may eventually identify specific cellular targets for possible therapeutic intervention.
Due to lack of deep understanding of different mesenchymal subpopulations, the precise identities and hierarchical relationships among HO contributing populations are still unclear.
Recent data suggest that HO and normal skeletogenesis have different cellular origins. Thus, additional studies are needed to explore potential disease-specific loci for future therapeutic intervention. 
